Vassilakopoulou, M., Togun, T., Dafni, U., Cheng, H., Bordeaux, J., Neumeister, V. M., . . . Psyrri, A. (2014). In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients. Public Library of Science.
Chicago Stili AlıntıVassilakopoulou, Maria, et al. In Situ Quantitative Measurement of HER2mRNA Predicts Benefit From Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients. Public Library of Science, 2014.
MLA AlıntıVassilakopoulou, Maria, et al. In Situ Quantitative Measurement of HER2mRNA Predicts Benefit From Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients. Public Library of Science, 2014.